Is weekly paclitaxel superior to paclitaxel given every 3 weeks? Results of a phase II trial.
Twenty-four patients previously treated with platinum containing regimens with stage IIIB-IV non-small-cell lung cancer (NSCLC) participated in the study. Sequential cohorts of patients were treated with 60 and 90 mg/m(2) of Paclitaxel per week. Paclitaxel was administered weekly over 1 h infusion for 6 consecutive weeks followed by 2 weeks without treatment (8-week cycle). A total of 252 treatments were administered to the 24 patients. In 29 (12%) of 252 treatments grade 2 granulocytopenia was observed while four patients (17%) developed grade 2 neuropathy. Seven patients (29%) achieved a partial response and five (21%) had stable disease. Paclitaxel 90 mg/m(2) per week as salvage treatment is well tolerated and has shown promising activity in patients with NSCLC who progress after platinum treatment.
Koumakis
George
G
B' Medical Oncology Department, Saint Savas Oncology Hospital, Hellenic Cancer Institute, 171 Alexandras Avenue, 115 22 Athens, Greece.
Demiri
Matina
M
Barbounis
Vassilios
V
Vassilomanolakis
Michail
M
Gontikakis
Emmanuel
E
Pamouksoglou
Philip
P
Dahabre
Jabrahel
J
Efremidis
Anna P
AP
D000328:Adult; D000368:Aged; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D015996:Survival Rate; D013997:Time Factors
D017239:Paclitaxel